PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Sep 11

PMID 39258975

Authors

Khaled Mohamed Nassar

Xue Yang

Adriana Baker

Rahul Gopalam

William C Arnold

Timilehin T Adeniran

Marian H Hernandez Fernandez

Megharani Mahajan

Zhao Lai

Yidong Chen

Gangadhara R Sareddy

Suryavathi Viswanadhapalli

Lu-Zhe Sun

Ratna K Vadlamudi

Uday P Pratap

Affiliations

Soon will be listed here.

Abstract

Significance: HCC is one of the leading causes of cancer fatalities in the United States. Effective targeted therapeutics for HCC are urgently needed. In this study, we show that PELP1 proto-oncogene is crucial to HCC progression and that PELP1 inhibition reduced HCC cell proliferation in vitro and in vivo. Our results imply that PELP1-targeted drugs like SMIP34 may be useful as new therapeutic agents for HCC treatment.

Citing Articles

Lnc-EST885 promotes hepatocellular carcinoma metastasis through PI3K / AKT pathway by interaction with TRAF4.

Zhu S, Wang G, Zhang Y, Zou M, Li Z, Qu S Transl Oncol. 2024; 52():102254.

PMID: 39721246 PMC: 11732567. DOI: 10.1016/j.tranon.2024.102254.

References

Wan J, Li X . PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells. Oncol Rep. 2012; 28(6):2035-42. DOI: 10.3892/or.2012.2038. View

Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C . Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012; 14(4):R108. PMC: 3680946. DOI: 10.1186/bcr3229. View

Gonugunta V, Sareddy G, Krishnan S, Cortez V, Roy S, Tekmal R . Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance. Mol Cancer Ther. 2014; 13(6):1578-88. PMC: 4226651. DOI: 10.1158/1535-7163.MCT-13-0877. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Vallabhaneni S, Nair B, Cortez V, Challa R, Chakravarty D, Tekmal R . Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat. 2010; 130(2):377-85. PMC: 3243930. DOI: 10.1007/s10549-010-1312-2. View

Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes S, Hsieh J . Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol Endocrinol. 2012; 26(4):550-61. PMC: 5417135. DOI: 10.1210/me.2011-1101. View

Oh J, Won Jun D . The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol. 2023; 29(2):355-357. PMC: 10121295. DOI: 10.3350/cmh.2023.0070. View

Luo Y, Li M, Pratap U, Viswanadhapalli S, Liu J, Venkata P . PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway. Mol Carcinog. 2019; 59(3):281-292. PMC: 7021561. DOI: 10.1002/mc.23152. View

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

10.

Sareddy G, Vadlamudi R . PELP1: Structure, biological function and clinical significance. Gene. 2016; 585(1):128-134. PMC: 4838531. DOI: 10.1016/j.gene.2016.03.017. View

11.

Roy S, Gonugunta V, Bandyopadhyay A, Rao M, Goodall G, Sun L . Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2013; 33(28):3707-16. PMC: 3935988. DOI: 10.1038/onc.2013.332. View

12.

Singal A, Nehra M, Adams-Huet B, Yopp A, Tiro J, Marrero J . Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol. 2013; 108(3):425-32. PMC: 5560895. DOI: 10.1038/ajg.2012.449. View

13.

Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B . Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008; 68(16):6779-88. PMC: 2587454. DOI: 10.1158/0008-5472.CAN-08-0742. View

14.

Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad I . Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44(6):694-8. PMC: 3819251. DOI: 10.1038/ng.2256. View

15.

Chakravarty D, Roy S, Babu C, Dandamudi R, Curiel T, Vivas-Mejia P . Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011; 17(8):2250-9. PMC: 3731129. DOI: 10.1158/1078-0432.CCR-10-2718. View

16.

Bartha A, Gyorffy B . TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int J Mol Sci. 2021; 22(5). PMC: 7961455. DOI: 10.3390/ijms22052622. View

17.

Vadlamudi R, Wang R, Mazumdar A, Kim Y, Shin J, Sahin A . Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem. 2001; 276(41):38272-9. DOI: 10.1074/jbc.M103783200. View

18.

Truong T, Benner E, Hagen K, Temiz N, Perez Kerkvliet C, Wang Y . PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER breast cancer. Oncogene. 2021; 40(25):4384-4397. PMC: 8238912. DOI: 10.1038/s41388-021-01871-w. View

19.

Kashiwaya K, Nakagawa H, Hosokawa M, Mochizuki Y, Ueda K, Piao L . Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells. Cancer Res. 2010; 70(10):4024-33. DOI: 10.1158/0008-5472.CAN-09-4444. View

20.

Pratap U, Sareddy G, Liu Z, Pitta Venkata P, Liu J, Tang W . Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. Neurooncol Adv. 2021; 3(1):vdab099. PMC: 8412056. DOI: 10.1093/noajnl/vdab099. View